Reuters logo
BRIEF-Merrimack Pharmaceuticals posts results from refractory solid tumor study
2016年6月6日 / 中午11点42分 / 1 年前

BRIEF-Merrimack Pharmaceuticals posts results from refractory solid tumor study

June 6 (Reuters) - Merrimack Pharmaceuticals Inc :

* Announced results from final analysis of phase 1 study of mm-151 in patients with refractory solid tumors

* Final analysis of first-in-human phase 1 study of mm-151 shows positive clinical activity in multiple solid tumor types

* Objective response observed in 21 percent of evaluable patients in Metastatic Colorectal Cancer (CRC) cohort

* Reduction in tumor size observed in 54 percent of patients in Metastatic Colorectal Cancer (CRC) cohort

* Most common adverse events reported were rash, hypomagnesemia, fatigue and diarrhea in monotherapy cohorts Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below